GEMSTONE-304
Regimen
- Experimental
- sugemalimab + cisplatin/5-FU
- Control
- placebo + cisplatin/5-FU
Population
Previously untreated unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC)
Key finding
mPFS 6.2 vs 5.4 mo (HR 0.67, p=0.0002); mOS 15.3 vs 11.5 mo (HR 0.70, p=0.008); ORR 60.1% vs 45.2%; both primary endpoints met
Source: PMID 38302715